The researchers concluded that PPARγ, induced by rosiglitazone, blocks the activation of HSCs and eliminates the expression of TGF-β1 and CTGF, thus improving liver fibrosis (Nan et al., 2009). Here, PPARG is linked to Hepatic fibrosis.